NASDAQ OMX

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

Dela

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET

UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments.

To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days.

About Merus N.V.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus' most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus' website, www.merus.nl.

Contacts:

Investors:
Kimberly Minarovich 
+1 646-368-8014
kimberly@argotpartners.com

Media:
David Rosen
+1 212-600-1902 
David.rosen@argotpartners.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Antalet registreringar fortsätter i explosiv takt på BIMobject Cloud - 800 000 användare passerades idag21.5.2018 12:08Pressmeddelande

Antalet totala registreringar av användare på portalen, i form av professionella arkitekter, ingenjörer, föreskrivare, byggbolag och designers uppgår nu till över 800 000. Bara i år har 150 000 nya användare tillkommit. Detta innebär att företaget är i linje med sin plan att nå milstolpen 1 miljon användare i slutet av året. BIMobject Cloud har även genererat dryga 1 miljon nedladdningar per månad i januari och februari under 2018 samt ökat till närmare 1,3 miljoner nedladdningar per månad under mars och april. Detta innebär en ökning med 30%. Totalt har 23 800 000 nedladdningar skett sedan BIMobject Cloud lanserades under 2012. För mer information, vänligen kontakta: Stefan Larsson - CEO Tel: +46 40 - 685 29 00 E-mail: press@bimobject.com Om BIMobject AB BIMobject är ett svenskt teknologiföretag med global närvaro som ligger i framkanten av byggindustrins digitalisering. BIMobject erbjuder en molnbaserad plattform som genom kraftfull teknologi tillgängliggör digital produktinformation

Sciaky Receives Order for Multiple Electron Beam Additive Manufacturing (EBAM®) Systems to Strengthen America's Defense and Power Generation Programs21.5.2018 09:00Pressmeddelande

CHICAGO, May 21, 2018 (GLOBE NEWSWIRE) -- Sciaky, Inc., a subsidiary of Phillips Service Industries, Inc. (PSI) and leading provider of metal additive manufacturing (AM) solutions, announced today that it has received an order for multiple Electron Beam Additive Manufacturing (EBAM®) systems to bolster the nation's defense and power generation programs. Details of the project are confidential. "Sciaky has a long history of providing innovative solutions to America's military and power generation initiatives," said Scott Phillips, President and CEO of Sciaky, Inc. "Our EBAM process is the only industrial-grade metal 3D printing technology to produce large-scale parts for land, sea, air, and space applications." As the most widely scalable metal additive manufacturing solution in the industry (in terms of work envelope), Sciaky's EBAM systems can produce parts ranging from 8 inches (203 mm) to 19 feet (5.79 meters) in length. EBAM is also the fastest deposition process in the metal addit

Clean Motion skalar upp med mikrofabriker runt om i världen med hjälp av digital masterfabrik från Siemens.21.5.2018 08:11Pressmeddelande

Elfordonstillverkaren Clean Motion, tillverkarare av den elektriska trehjulingen Zbee, har en global expansionsstrategi som bygger på distribuerad lokal tillverkning i många, mindre fabriker nära slutkunden. För att lyckas med en sådan expansion är det viktigt att säkerställa en digitalt definierad produkt och tillverkningsprocess tillsammans med en centralt kontrollerad leverantörskedja. Clean Motion tar nu nästa steg i sin digitaliseringsprocess tillsammans med Siemens, där digitala tvillingar möjliggör en fullt digitaliserad virtuell produkt, tillverkningsprocess och fabrik. Clean Motion har inlett ett samarbete med Siemens och Virtual Engineering för att realisera sin digitaliseringsstrategi. Som en del av den strategin kommer en digital masterfabrik att byggas i Siemens PLM mjukvara. Fabriken kommer sedan möjliggöra anpassningar för införandet av nya varianter samt optimering av produktionsflöden. Clean Motion kommer kunna bygga upp ett stort antal oberoende fysiska fabriker och s

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressmeddelande

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

BIMobject AB: BIMobject publicerar årsredovisning för 201718.5.2018 17:25Pressmeddelande

BIMobject, som digitaliserar byggbranschen bland annat via molnbaserade plattformar, har idag publicerat årsredovisningen för 2017 på bolagets hemsida. "Det är med stolthet vi offentliggör årsredovisningen för året 2017 - ett år som för oss inte kan beskrivas annat än som 'explosivt'. Det är fantastiskt roligt att se hur vi fortsätter att effektivisera branscher som äntligen börjar se nyttan och digitaliseringens fulla potential. Att vi sedan har fyra starka trender som ger oss vind i seglet gör framtiden ännu mer lockande. Nu är vi i ett spännande 2018 där vi bland annat ser fram emot att passera milstolpen 1 miljon användare", säger Stefan Larsson, VD på BIMobject. Årsredovisningen finns tillgänglig för nedladdning på: http://info.bimobject.com/bimobject_data/documents/Documents/2017/bimobject-%C3%A5rsredovisning-2017.pdf För mer information, vänligen kontakta: Stefan Hansson - CFO Tel: +46 40 - 685 29 00 E-mail: press@bimobject.com ______________________________________________ Denn

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressmeddelande

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum